 | | Vol. 12.21 – 11 June, 2021 |
| |
|
|
| Single-cell-based approaches revealed striking temporal changes to the transcriptome and chromatin accessibility which have identified the emergence of distinct cell populations, marked by differential expression of Ascl1 and Pou2f3, during the transition to neuroendocrine prostate cancer.
[Nature Communications] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| 211At-VK-02-90-Lu was selected and evaluated in cell uptake and internalization studies, biodistribution, and prostate-specific membrane antigen (PSMA)+ PC3 PIP tumor growth control in experimental flank and metastatic models.
[Journal of Nuclear Medicine] |
|
|
|
| Investigators found a total of 137 genes were ectopically expressed in eight cancer types, of which Holliday junction recognition protein (HJURP) was significantly upregulated in prostate cancer.
[Cell Death & Disease] |
|
|
|
| NUC-1031 preferentially targeted leukemic stem cells in primary AML samples and cancer stem cells in the prostate cancer cell line, LNCaP.
[Journal of Medicinal Chemistry] |
|
|
|
| Researchers explored anti-prostate cancer activity in a polyphenol-rich fraction of Bergenia ligulata, a plant used in Indian traditional and folk medicine for its anti-inflammatory and antineoplastic properties.
[Free Radical Biology and Medicine] |
|
|
|
| The authors used preclinical experimental models to investigate whether an inactive form of receptor activator of nuclear factor kappa-B ligand (RANKL) affected bone metastasis in RANKL-induced prostate cancer.
[Scientific Reports] |
|
|
|
| Investigators showed that genetic deletion of MAP4K4 or pharmacological inhibition of its encoded kinase, HGK, inhibited metastatic prostate cancer cells migration and clonogenic properties.
[Scientific Reports] |
|
|
|
| Pharmacological inhibitors of the mammalian target of rapamycin (mTOR) markedly suppressed the mRNA level as well as the protein level of hyaluronan-mediated motility receptor (HMMR) in LNCaP and PC-3 cells.
[Biomolecules & Therapeutics] |
|
|
|
| Using genome-wide target capture of miRNAs and miRNA-binding sites followed by deep sequencing in prostate cancer cell lines, researchers identified prostate cancer-specific single nucleotide variants in mature miRNAs and their target binding sites.
[Journal of Human Genetics] |
|
|
|
|
| Scientists summarize the important roles of these three classes of noncoding RNA in drug resistance and the potential therapeutic applications in prostate cancer.
[Cell Death & Disease] |
|
|
|
|
| Francis Medical, Inc. announced positive results from the company’s VAPOR 1 clinical study evaluating the safety and efficacy of the company’s minimally invasive water vapor ablation therapy for treating prostate cancer.
[Francis Medical, Inc.] |
|
|
|
| Novartis AG announced that results of the Phase III VISION study evaluating 177Lu-PSMA-617, a targeted radioligand therapy, plus best standard of care (SOC) demonstrated significant improvement in overall survival compared to SOC alone, in patients with progressive PSMA-positive metastatic CRPC.
[Novartis AG] |
|
|
|
|
| June 21 – 24, 2021
Virtual |
|
|
|
|
|
| | University of Texas MD Anderson Cancer Center – Houston, Texas, United States |
|
|
|
| | Cedars-Sinai Medical Center – Los Angeles, California, United States |
|
|
|
| | H. Lee Moffitt Cancer Center – Tampa, Florida, United States |
|
|
|
| | Cleveland Clinic – Cleveland, Ohio, United States |
|
|
|
| | Peter MacCallum Cancer Centre – Victoria, Australia |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
